Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy

PURPOSE: To study the effectiveness of anti-CD20 (Rituximab, RTX, Rituxan®, Genentech Inc. USA) therapy in patients with severe, corticosteroid (CS)-resistant thyroid-associated ophthalmopathy (TAO). DESIGN: Retrospective interventional case series PARTICIPANTS: Six consecutive subjects with severe,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chong, Kelvin K.L., Khanna, Dinesh, Afifiyan, Nikoo F., Hwang, Catherine J, Lee, Diana K., Chokron Garneau, Helene, Goldberg, Robert A., Darwin, Christine H, Smith, Terry J, Douglas, Raymond S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2814962/
https://ncbi.nlm.nih.gov/pubmed/19818507
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ophtha.2009.05.029
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados